Score Breakdown
Dilution Forecast
Market Data
Source-Backed Evidence Depth
This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.
| Field | Current Value | Basis |
|---|---|---|
| DilutionScore | 65/100 | DilutionWatch score record |
| Shares Outstanding | 101.92M | Verified float table or market cache |
| Public Float | Not available | Verified float table or market cache |
| Market Cap | Not available | Market data cache |
| Cash Runway | 0.1 months | DilutionWatch score inputs |
| Shelf Capacity | None in current score inputs | SEC-derived dilution fields |
| ATM Capacity | None in current score inputs | SEC-derived dilution fields |
| Outstanding Warrants | 5.75M | SEC-derived dilution fields |
Recent source-backed SEC insight records available on this page: 2.
Recent SEC source mix: XBRL 2.
The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.
Institutional Holdings
Short Interest
Recent SEC Activity
Recent News
Factual STLNW Dilution Snapshot
Starling Oncology, Inc. (STLNW) has a DilutionScore of 65/100, rated High dilution risk. Score date: September 09, 2026.
- Stored outstanding warrants: 5.8M.
- Recent SEC activity tracked for STLNW: xbrl on 2025-12-31; xbrl on 2025-03-24.
- Score coverage note: Float Risk is excluded because public-float data is unavailable.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Related Stocks — HIGH Risk
Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:
Score Coverage Note
- Float Risk is excluded because public-float data is unavailable.